Therefore, we hypothesize that a less risky surgical method (compared to DBS) accompanied by a potentially more effective (chemogenetic) modulation of LH or other obesity-related brain circuits might provide a new therapeutic alternative to severely obese patients next to pharmacotherapy and bariatric surgery. The gene discussed is PLOD1; the disease is obesity disorder.